Talks (142)
defining triple negative breast cancer
May 30
Flutofastat FDA approval
May 30
use of CDK4/6 inhibitors in early breast
May 27
ASCO plenary preview
May 26
ASCO preview
May 26
Epcoritamab FDA approval
May 24
FLAURA2 part 2
May 17
FLAURA2 part 1
May 17
COSMIC 313
May 12
updated results from KRYSTAL-1
May 09
ASCO 23 abstracts
May 09
sunlight trial in colon cancer
May 09
Breast Cancer
Mar 08
Paid Leave & Screening
Mar 08
Top 5 Female DOLs
Mar 08
Atorvastatin
Mar 06
aspirin
Mar 03
Mediterranean diet
Mar 01
LAT1 inhibitor
Feb 22
SBRT
Feb 22
antibiotics
Feb 22
bariatric surgery
Feb 08
tobacco
Feb 08
discount drugs
Feb 08
Care gap
Feb 06
Clinical trials
Feb 06
SARS-CoV-2
Feb 01
tucatinib
Jan 25
CZ
Jan 18
vit D
Jan 18
Capecitabine tablets
Jan 11
menopause
Jan 06
Adstiladrin
Jan 04
carcinoma
Dec 21
Modelling in Onc.
Aug 03
Precision Oncology
Aug 03
Innovation in Onc.
Aug 03
Early Stage TNBC
Mar 29
Dr. Kalinsky
Mar 29
GC Survival
Mar 08
Levatinib in HCC
Mar 08
Taxanes /Ramucirumab
Mar 08
Frontline Poziotinib
Mar 08
New FDA Approval
Mar 08
Neoadjuvant IO
Mar 07
HER2+BC
Mar 07
Dr. Tolaney
Mar 07
Non-Coding RNAs
Mar 04
Dr. Hurvitz
Mar 04
Dr. O’Shaughnessy
Mar 04
HER2-Low BC
Feb 28
Non-Coding RNAs
Feb 28
Using Bioinformatics
Jan 20
FDA Review
Jan 20
ERAS Protocol
Jan 18
Biomarkers in GC
Jan 18
CDK4/6 Inhibitors
Jan 13
Risk Stratification
Jan 13
RG vs LG
Jan 12
Chemoradiotherapy
Jan 12